80 likes | 225 Views
Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia A Randomized, Placebo-controlled Trial (MMM 300). Orgogozo J.M., Rigaud A.S., Stöffler A., Möbius H.J., and Forette F. Stroke 2002, 33:1834-1839. Study Design. No. of patients N = 321
E N D
Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia A Randomized, Placebo-controlled Trial (MMM 300) Orgogozo J.M., Rigaud A.S., Stöffler A., Möbius H.J., and Forette F. Stroke 2002, 33:1834-1839
Study Design No. of patients N = 321 Design Double-blind, randomized, placebo- controlled, multicenter study Diagnosis Probable VaD (acc. NINDS-AIREN, HIS 5) Age 60 (mean 76) Severity MMSE 12 - 20 (mean 16.9) Dose; duration 20 mg memantine/day; 28 weeks Primary efficacy Cognition: ADAS-cogparameters Global: CIBIC-Plus Secondary efficacy MMSE, GBS, NOSGER, CGI-Cparameters Orgogozo et al., Stroke 2002
Disposition of Patients Patients screenedN = 403 Screen failuresN = 82 (20%) Patients randomizedN = 321 PlaceboN = 156 (49%) MemantineN = 165 (51%) CompletedN = 118(76%) WithdrewN = 38(24%) CompletedN = 116(70%) WithdrewN = 49(30%) Orgogozo et al., Stroke 2002
19 20 21 22 23 24 * Memantine (20 mg/day) Placebo 0 12 28 Significant Benefit of Memantine on Cognition (ADAS-cog) ITT, LOCF ADAS-cog total score ADAS-cog total score Worsening Week *p = 0.0016 versus placebo Orgogozo et al., Stroke 2002
-2 -1 0 1 2 3 * Memantine (20 mg/day) Placebo 0 12 28 Significant Benefit of Memantine on Cognition (ADAS-cog) ITT, LOCF Mean change from baseline Improvement ADAS-cog score difference Worsening Week *p = 0.0016 versus placebo Orgogozo et al., Stroke 2002
19 18 17 16 Memantine (20 mg/day) Placebo * 0 28 Significant Benefit of Memantine on Cognition (MMSE) TPP, N = 188 MMSE analysis MMSE total score Worsening Week *p = 0.003 versus placebo Orgogozo et al., Stroke 2002
Good Safety and Tolerability of Memantine Adverse events in mild to moderate VaD (MMM300) Memantine Placebo Total no. of patients 165 (100%) 156 (100%) Total no. of patients with AEs 117 (70.9%) 104 (56.7%) Agitation 9 (5.5%) 11 (7.1%) Confusion 8 (4.8%) 8 (5.8%) Dizziness 8 (4.8%) 5 (3.2%) Bronchitis 6 (3.6%) 7 (4.5%) Urinary Tract Infection 5 (3.0%) 7 (4.5%) Cerebrovascular Disorder 6 (3.6%) 6 (3.8%) Depression 6 (3.6%) 5 (3.2%) Diarrhoea 5 (3.0%) 6 (3.8%) Hypertension 4 (2.4%) 7 (4.5%) Inflicted Injury 5 (3.0%) 6 (3.8%) Orgogozo et al., Stroke 2002
Summary • Significant cognitive benefit for patients with mild to moderate vascular dementia treated with memantine compared to placebo (ADAS-cog and MMSE ) • Good safety and tolerability of memantine Orgogozo et al., Stroke 2002